Humira (adalimumab) is used to treat several autoimmune conditions. The drug typically stays in your system for a few months after your final dose. This article explains how long Humira may remain in ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

The Food and Drug Administration has designated Celltrion’s Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Abbvie's Humira (adalimumab). Yuflyma is a high-concentration (100mg/ml) and ...